Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/19/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Mark Ashwell?

Mark A. Ashwell

Vice President and Head of Chemistry

ArQule , Inc.

HQ Phone:  (781) 994-0300

Direct Phone: (781) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

ArQule , Inc.

One Wall Street

Burlington, Massachusetts,01803

United States

Company Description

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that wi...more

Background Information

Employment History

Researcher

Wyeth


Affiliations

Nimbus Therapeutics LLC

Board Member


Education

Ph.D.


bachelor's degree

chemistry

University of Birmingham


doctorate

organic chemistry

University of Birmingham


Web References(24 Total References)


Nimbus

www.nimbustx.com [cached]

Mark Ashwell, Ph.D.
Senior Vice President, Head of Chemistry Mark Ashwell, Ph.D. Senior Vice President, Head of Chemistry Dr. Mark Ashwell is Senior Vice President, Head of Chemistry at Nimbus. He has worked in R&D in both biotech and pharma for more than 25 years, with experience advancing research portfolios across multiple target classes and therapeutic areas. Mark specializes in the fields of drug discovery research, technology utilization, portfolio creation and management, and business development. Before joining Nimbus, he was Principal Consultant at Ashwell Consulting Group, where he provided strategic counsel to biotech, pharma, academia and R&D service industries in a number of areas including oncology, medicinal chemistry, structure-based drug discovery, intellectual property creation and atypical modes of target inhibition. Prior to this, Mark was Vice President, Head of Chemistry at ArQule Inc., where he built and managed a cross functional team responsible for multiple research collaborations, which significantly contributed to the delivery of eight INDs into clinical development. Mark was an inventor and key driver of the ArQule Kinase Inhibition Technology Platform (AKIP™), which was leveraged to establish strategic R&D partnerships with global pharmaceutical companies, including Daiichi-Sankyo. Mark completed two postdoctoral research fellowships, worked as an NIH-funded World Health Organization consultant, and received his B.Sc. in Chemistry and his Ph.D. in Organic Chemistry from the University of Birmingham in the U.K. He has published over 30 peer-reviewed research papers and is listed as an inventor on 50 U.S.-granted patents and over 30 international filings.


nimbustx.com

Mark Ashwell, ph.d.
Head of Chemistry Mark Ashwell, Ph.D. Head of Chemistry Dr. Mark Ashwell is Head of Chemistry at Nimbus. He has worked in R&D in both biotech and pharma for more than 25 years, with experience advancing research portfolios across multiple target classes and therapeutic areas. Mark specializes in the fields of drug discovery research, technology utilization, portfolio creation and management, and business development. Before joining Nimbus, he was Principal Consultant at Ashwell Consulting Group, where he provided strategic counsel to biotech, pharma, academia and R&D service industries in a number of areas including oncology, medicinal chemistry, structure-based drug discovery, intellectual property creation and atypical modes of target inhibition. Prior to this, Mark was Vice President, Head of Chemistry at ArQule Inc., where he built and managed a cross functional team responsible for multiple research collaborations, which significantly contributed to the delivery of eight INDs into clinical development. Mark was an inventor and key driver of the ArQule Kinase Inhibition Technology Platform (AKIP™), which was leveraged to establish strategic R&D partnerships with global pharmaceutical companies, including Daiichi-Sankyo. Mark completed two postdoctoral research fellowships, worked as an NIH-funded World Health Organization consultant, and received his B.Sc. in Chemistry and his Ph.D. in Organic Chemistry from the University of Birmingham in the U.K. He has published over 30 peer-reviewed research papers and is listed as an inventor on 50 U.S.-granted patents and over 30 international filings.


CHI's Molecular Medicine Tri-Conference

www.chimolecularmed.com [cached]

Dr. Mark Ashwell, Director of Chemistry, Arqule Inc.Dr. Mark Ashwell, Director of Medicinal Chemistry, Arqule, Inc.


Nimbus Therapeutics Appoints Mark Ashwell, Ph.D., as Head of Chemistry | Business Wire

www.businesswire.com [cached]

Nimbus Therapeutics Appoints Mark Ashwell, Ph.D., as Head of Chemistry
January 05, 2017 07:30 AM Eastern Standard Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company applying deep computational chemistry expertise throughout drug discovery and development, today announced that Mark Ashwell, Ph.D., has joined the company as the Head of Chemistry. The appointment further expands Nimbus' core development capabilities and bolsters the senior leadership team as the company works to advance multiple promising pipeline candidates toward clinical-stage development. As Head of Chemistry, Dr. Ashwell's responsibilities include maximizing Nimbus' unique relationship with founding partner Schrdinger while also integrating new technologies and collaborators into Nimbus' cutting-edge platform and approach to drug discovery, helping to realize Nimbus' vision of creating breakthroughs by design while tackling tough targets like Tyk2, STING and others in the Nimbus pipeline. An accomplished R&D leader, Dr. Ashwell served as the long-time Head of Chemistry at ArQule, where he led eight drug candidates from discovery and early development into clinical-stage testing in cancer and rare diseases. Furthermore, he was an inventor of the ArQule Kinase Inhibition Technology Platform, the company's discovery engine, which yielded product opportunities that led to productive R&D partnerships with global pharmaceutical companies. "Mark is a terrific addition to our high-performing team, whose technical expertise and entrepreneurial vision will help drive our continued success discovering and developing novel therapies for some of the most promising targets in drug development," said Don Nicholson, Ph.D., Chief Executive Officer at Nimbus. "Building on the strong foundation laid by our founding Head of Chemistry, Dr. Ron Wester, Mark will work alongside our Chief Scientific Officer, Dr. Rosana Kapeller, and Head of Preclinical Research and Early Development, Dr. Wes Westlin, to accelerate our next breakthroughs in discovery." Nimbus also announced today that Dr. Wester has assumed the role of senior emeritus advisor and will remain with Nimbus to support Dr. Ashwell. In addition to his experience at ArQule, Dr. Ashwell has served as a consultant to numerous drug development teams in industry and academia across a wide range of areas that included oncology drug development, medicinal chemistry, structure-based drug discovery and intellectual property creation. Earlier in his career, he worked as a researcher at Wyeth and as an NIH-funded World Health Organization consultant. Dr. Ashwell holds a doctorate in organic chemistry and a bachelor's degree in chemistry, both from the University of Birmingham in the U.K., and completed two postdoctoral research fellowships. He has published over 30 peer-reviewed research papers and is listed as an inventor on 50 U.S.-granted patents and more than 30 international filings. Nimbus Therapeutics today announced that Mark Ashwell, Ph.D., has joined the company as the Head of Chemistry.


www.nimbustx.com

Nimbus Appoints Mark Ashwell, Ph.D., as Head of Chemistry
Nimbus Nimbus Appoints Mark Ashwell, Ph.D., as Head of Chemistry CAMBRIDGE, Mass. - Jan 5, 2017 - Nimbus Therapeutics, a biotechnology company applying deep computational chemistry expertise throughout drug discovery and development, today announced that Mark Ashwell, Ph.D., has joined the company as the Head of Chemistry. The appointment further expands Nimbus' core development capabilities and bolsters the senior leadership team as the company works to advance multiple promising pipeline candidates toward clinical-stage development. As Head of Chemistry, Dr. Ashwell's responsibilities include maximizing Nimbus' unique relationship with founding partner Schrödinger while also integrating new technologies and collaborators into Nimbus' cutting-edge platform and approach to drug discovery, helping to realize Nimbus' vision of creating breakthroughs by design while tackling tough targets like Tyk2, STING and others in the Nimbus pipeline. An accomplished R&D leader, Dr. Ashwell served as the long-time Head of Chemistry at ArQule, where he led eight drug candidates from discovery and early development into clinical-stage testing, in cancer and rare diseases. Furthermore, he was an inventor of the ArQule Kinase Inhibition Technology Platform, the company's discovery engine, which yielded product opportunities that led to productive R&D partnerships with global pharmaceutical companies. "Mark is a terrific addition to our high-performing team, whose technical expertise and entrepreneurial vision will help drive our continued success discovering and developing novel therapies for some of the most promising targets in drug development," said Don Nicholson, Ph.D., Chief Executive Officer at Nimbus. "Building on the strong foundation laid by our founding Head of Chemistry, Dr. Ron Wester, Mark will work alongside our Chief Scientific Officer, Dr. Rosana Kapeller, and Head of Preclinical Research and Early Development, Dr. Wes Westlin, to accelerate our next breakthroughs in discovery." Nimbus also announced today that Dr. Wester has assumed the role of senior emeritus advisor and will remain with Nimbus to support Dr. Ashwell. In addition to his experience at ArQule, Dr. Ashwell has served as a consultant to numerous drug development teams in industry and academia across a wide range of areas that included oncology drug development, medicinal chemistry, structure-based drug discovery and intellectual property creation. Earlier in his career, he worked as a researcher at Wyeth and as an NIH-funded World Health Organization consultant. Dr. Ashwell holds a doctorate in organic chemistry and a bachelor's degree in chemistry, both from the University of Birmingham in the U.K., and completed two postdoctoral research fellowships. He has published over 30 peer-reviewed research papers and is listed as an inventor on 50 U.S.-granted patents and more than 30 international filings.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory